Christopher Cogle, M.D.

Christopher R Cogle, M.D.

(352) 733-0972

Request an Appointment

Publications

RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia
Cell Stem Cell
2020

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
International Journal of Molecular Sciences
2020

Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients
Hematology/oncology and stem cell therapy (Print)
2020

Clinical Application of Computational Methods in Precision Oncology: A Review
Jama Oncology
2020

Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis
Leukemia Research
2019

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study
Leukemia Research
2019

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
Clinical Lymphoma Myeloma & Leukemia
2019

Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia
Leukemia Research
2019

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise
Journal of Clinical Oncology
2019

HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice
Cancer cell (Online)
2019

Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?
International Journal of Environmental Research and Public Health
2019

Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics
Leukemia Research
2019

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Blood Advances
2019

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Cancers
2019

Using Social Media to Assess Care Coordination Goals and Plans for Leukemia Patients and Survivors

2018

Poor Peripheral Blood Stem Cell Mobilization Affects Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Journal of Clinical Apheresis
2018

Infusion of Alloanergized Donor Lymphocytes After Cd34-Selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation
Clinical Cancer Research
2018

Functional genomic landscape of acute myeloid leukaemia
Nature
2018

Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (Cxl Series) for Its Selective Antiproliferative Activity Toward Multidrug-Resistant Cancer Cells
Journal Of Medicinal Chemistry
2018

Ex-Vivo Sensitivity Profiling to Guide Clinical Decision Making in Acute Myeloid Leukemia: a Pilot Study
Leukemia Research
2018

Ctcf Boundary Remodels Chromatin Domain and Drives Aberrant Hox Gene Transcription in Acute Myeloid Leukemia
Blood
2018

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
Leukemia Research
2018

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
Oncologist
2017

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction Il-1 Beta- and Il-6-Related Impairment of Bone Marrow Function

2017

Minimal Residual Disease By Either Flow Cytometry or Cytogenetics Prior to An Allogeneic Hematopoietic Stem Cell Transplant Is Associated With Poor Outcome in Acute Myeloid Leukemia
Blood Cancer Journal
2017

Ex Vivo Oncolytic Virotherapy With Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft Versus Tumor

2017

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence
Leukemia Research
2017

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
Current Hematologic Malignancy Reports
2017

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
Viruses-Basel
2016

Ex Vivo Virotherapy With Myxoma Virus Does Not Impair Hematopoietic Stem and Progenitor Cells
Cytotherapy
2016

Efficacy and Safety of Extended Dosing Schedules of Cc-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

2016

Effect of Melphalan 140 Mg/M(2) Vs 200 Mg/M(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation-a Single Center Experience
Clinical Transplantation
2016

Cost-Effectiveness of Treatments for High-Risk Myelodysplastic Syndromes After Failure of First-Line Hypomethylating Agent Therapy
Expert Review of Pharmacoeconomics & Outcomes Research
2016

Connect Mds/Aml: Design of the Myelodysplastic Syndromes and Acute Myeloid Leukemia Disease Registry, a Prospective Observational Cohort Study
Bmc Cancer
2016

Clinical Significance of in Vivo Cytarabine-Induced Gene Expression Signature in Aml
Leukemia & Lymphoma
2016

Circulating Progenitor Cells and Coronary Microvascular Dysfunction: Results From the Nhlbi-Sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (Wise-Cvd)
Atherosclerosis
2016

Chemosensitizing AML cells by targeting bone marrow endothelial cells
Experimental Hematology
2016

Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells
Hypertension
2016

A New Model to Predict Remission Status in Aml Patients Based on Day 14 Bone Marrow Biopsy
Leukemia Research
2016

Vitamin D Effect on Umbilical Cord Blood Characteristics: a Comparison Between African Americans and Caucasians
Transfusion
2015

Prevention of Ebv Lymphoma Development By Oncolytic Myxoma Virus in a Murine Xenograft Model of Post-Transplant Lymphoproliferative Disease
Biochemical and Biophysical Research Communications
2015

Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
2015

Pharmacokinetics and Pharmacodynamics With Extended Dosing of Cc-486 in Patients With Hematologic Malignancies
PLoS One
2015

Endothelial Cell Derived Angiocrine Support of Acute Myeloid Leukemia Targeted By Receptor Tyrosine Kinase Inhibition
Leukemia Research
2015

Bone Marrow Characteristics Associated With Changes in Infarct Size After Stemi a Biorepository Evaluation From the Cctrn Time Trial

2015

Response To Letter Regarding Article, 'a Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction: Bm Cd34, Cd11B and Clonogenic Capacity as Biomarkers for Clinical Outcomesandquot;

2014

Radiation Alone for Solid Tumors and the Questionable Development of Therapy-Related Myelodysplastic Syndromes

2014

Myelodysplastic Syndromes Management and Treatment: a Conceptual Framework
Haematologica
2014

Mapping Hematopoiesis in a Fully Regenerative Vertebrate: the Axolotl
Blood
2014

High Rate of Uncaptured Myelodysplastic Syndrome Cases and An Improved Method of Case Ascertainment
Leukemia Research
2014

Functional Integration of Acute Myeloid Leukemia Into the Vascular Niche

2014

Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction Bm Cd34, Cd11B, and Clonogenic Capacity as Biomarkers for Clinical Outcomes

2014

Angiotensin II Regulates Hematopoietic Stem Cell Proliferation, Differentiation and Engraftment Efficacy
Experimental Hematology
2014

A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Human Gene Therapy
2014

Variable and Decreased Clonogenic Activity of Autologous Bone Marrow in Cell Therapy Patients With Ischemic Heart Disease, and Cd34 as a Biomarker for Clinical Outcomes: Results From the Cardiovascular Cell Therapy Research Network (Cctrn)
Circulation
2013

The Nhlbi Time Trial: One-Year Results
Circulation
2013

Parp1 Is Required for Chromosomal Translocations
Blood
2013

Overcoming Chronic Myeloid Leukemia Stem Cell Resistance To Imatinib By Also Targeting Jak2

2013

A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials
Current Atherosclerosis Reports
2013

Virotherapy Using Myxoma Virus Prevents Lethal Graft-Versus-Host Disease Following Xeno-Transplantation With Primary Human Hematopoietic Stem Cells
PLoS One
2012

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells By Depolymerizing the Microtubule Cytoskeleton
Blood
2012

Underreporting of Myeloid Malignancies By United States Cancer Registries

2012

The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis
American Journal of Pathology
2012

The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: the Nhlbi and Cctrn Time Trial
Circulation
2012

Single Versus Tandem Autologous Stem Cell Transplantation (Asct) for Multiple Myeloma Patients and Role of Second Salvage Transplant: a Single Center Prospective Phase Ii Study
Biology of Blood and Marrow Transplantation
2012

Selective Purging of Human Multiple Myeloma Cells From Autologous Stem Cell Transplantation Grafts Using Oncolytic Myxoma Virus
Biology of Blood and Marrow Transplantation
2012

Safety and Efficacy of Oral Azacitidine (Cc-486) Administered in Extended Treatment Schedules To Patients With Lower-Risk Myelodysplastic Syndromes
Blood
2012

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update
Blood
2012

Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood
2012

Extended Dosing of Oral Azacitidine (Cc-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Blood
2012

Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery On Left Ventricular Function After Acute Myocardial Infarction the Time Randomized Trial
Jama-Journal of the American Medical Association
2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells On Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure the Focus-Cctrn Trial
Jama-Journal of the American Medical Association
2012

Characteristics of Thawed Autologous Umbilical Cord Blood
Transfusion
2012

Acute Myeloid Leukemia Targeting By Myxoma Virus in Vivo Depends On Cell Binding But Not Permissiveness To Infection in Vitro
Leukemia Research
2012

A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood
2012

The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-Mediated Human Pathological Cell Growth in Vitro and in Vivo
Journal of Biological Chemistry
2011

The Jak2 Inhibitor, G6, Alleviates Jak2-V617F-Mediated Myeloproliferative Neoplasia By Providing Significant Therapeutic Efficacy To the Bone Marrow
Neoplasia
2011

Results From Latetime: a Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two To Three Weeks Following Acute Myocardial Infarction
Circulation
2011

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Journal of Clinical Oncology
2011

Incidence of the Myelodysplastic Syndromes Using a Novel Claims-Based Algorithm: High Number of Uncaptured Cases By Cancer Registries
Blood
2011

Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 To 3 Weeks Following Acute Myocardial Infarction On Left Ventricular Function the Latetime Randomized Trial
Jama-Journal of the American Medical Association
2011

Diagnostic Testing, Treatment, Cost of Care, and Survival Among Registered and Non-Registered Patients With Myelodysplastic Syndromes
Leukemia Research
2011

Developing Mechanistic Insights Into Cardiovascular Cell Therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory Rationale
American Heart Journal
2011

Oncolytic Viral Purging of Leukemic Hematopoietic Stem and Progenitor Cells With Myxoma Virus
Cytokine and Growth Factor Reviews
2010

Multicenter Cell Processing for Cardiovascular Regenerative Medicine Applications: the Cardiovascular Cell Therapy Research Network (Cctrn) Experience
Cytotherapy
2010

Leukemia Regression By Vascular Disruption and Antiangiogenic Therapy
Blood
2010

Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical Advances in Hematology and Oncology
2010

High Rate of Uncaptured Myelodysplastic Syndrome Cases At the State Cancer Registry Level
Blood
2010

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: a Phase I Study
Blood
2010

Acute Myeloid Leukemia Cells Depend On Vegf, Pdgfr and Scf Receptor Signaling: Leukemia Regression With Pazopanib
Blood
2010

Time From Onset of Acute Anterior Myocardial Infarction Negatively Influences Bone Marrow Cell Function: Preliminary Data From the Nhlbi Cctrn Ancillary Studies
Circulation
2009

Rationale and Design for Time: a Phase Ii, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bone Marrow Mononuclear Cells After Acute Myocardial Infarction
American Heart Journal
2009

Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells

2009

Impact of Azacytidine Induction Chemotherapies On Post-Transplant Outcomes in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology
2009

Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge
Blood
2009

Bone Marrow Stem and Progenitor Cell Contribution To Neovasculogenesis Is Dependent On Model System With Sdf-1 as a Permissive Trigger
Blood
2009

Aml Regression By Vascular Disruption With Oxi4503 and Anti-Angiogenesis With Bevacizumab.
Blood
2009

Aldehyde Dehydrogenase Activity as a Functional Marker for Lung Cancer
Chemico-Biological Interactions
2009

A Phase 1, Open-Label, Dose-Escalation Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml)
Blood
2009

A Comparative Pharmacokinetic/Pharmacodynamic (Pk/Pd) Evaluation of Azacitidine Following Subcutaneous (Sc) and Oral Administration in Subjects With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml), Results From a Phase 1 Study
Blood
2009

Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple
Biology of Blood and Marrow Transplantation
2008

Marrow Cell Therapies for Cardiovascular Diseases
Experimental Hematology
2008

Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry.

2007

Stem cell research.
Paediatric respiratory reviews
2006

Developmental differences in megakaryocyte maturation are determined by the microenvironment.

2005

The hemangioblast: cradle to clinic
Experimental Hematology
2004

Adult human hematopoietic cells provide functional hemangioblast activity
Blood
2004

Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia.
Clinical Advances in Hematology and Oncology
2003

Research Interests

Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he began translating research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of Health, and Florida Governor on evidence-based strategies to reduce the state's cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in Health and Medicine Scholar. As a Scholar he works to increase access to high quality health care by studying and improving health policies of government entities and health systems.

Active Research Studies